Bioorganic and Medicinal Chemistry Letters p. 2957 - 2960 (2018)
Update date:2022-08-03
Topics:
Huang, Yaping
Sun, Geng
Wang, Pengfei
Shi, Rui
Zhang, Yanchun
Wen, Xiaoan
Sun, Hongbin
Chen, Caiping
In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. Most importantly, H20 displayed definite inhibitory activity against Complex I.
View MoreLanzhou huibang biological chemical technology Co., LTD
Contact:0931-7843964
Address:NO.2011,Yannan Road,Chengguan,
Fuxin Jintelai Fluorin Chemical Co., Ltd.
Contact:+86-0418-8229599
Address:, 7th Huagong Road, Fluorine industry development zone (Yimatu Town,Fumeng County),Fuxin City, Liaoning Province, China
Anhui Asahikasei Chemical Co., Ltd
Contact:86-551-4259770
Address:No. 88 Linquan Road Hefei Anhui China
Changzhou Ansciep Chemical Co.,Ltd.
Contact:+86 519 8630 5871
Address:A-710 Boan International, 8 East Guangdian Road,Wujin,Changzhou
Suzhou Ryan Pharmachem Technology Co.,Ltd
Contact:+86-0512-68780025
Address:B-301,No.2 Taishan Road,Suzhou New District,Jiangsu,P.R. China
Doi:10.1016/j.tet.2013.05.064
(2013)Doi:10.1007/s10593-005-0179-3
(2005)Doi:10.1016/S0040-4039(01)91051-2
(1984)Doi:10.1016/j.tet.2006.12.088
(2007)Doi:10.1016/j.tetlet.2006.12.109
(2007)Doi:10.1016/j.apcata.2014.08.009
(2014)